Drug intelligence / Profile preview

Methyl Folate

Development stage: Unknown
Lead developer: Orchidia Pharma
Modality: Small Molecules
Administration: Oral

Overview

**Methyl Folate** is an oral Orchidia Pharma dietary-supplement product supplied as capsules. The marketed formulation provides 800 mcg of active 5-methyltetrahydrofolate and 1,000 mcg of vitamin B12; retailer composition information identifies the B12 ingredient as methylcobalamin. It is a fixed-dose nutritional combination intended to support folate and vitamin B12 status, including one-carbon metabolism, DNA synthesis, and red-blood-cell formation. ([eshop.orchidiapharma.com](https://eshop.orchidiapharma.com/products/methyl-folate))

Brand names: Methyl Folate

Targets

MTR (Methionine synthase)

Beyond the preview

Go deeper on Methyl Folate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Methyl Folate.

Explore the full profile